156 related articles for article (PubMed ID: 36095125)
21. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
Leitch HA; Gattermann N
Crit Rev Oncol Hematol; 2019 Sep; 141():54-72. PubMed ID: 31228649
[TBL] [Abstract][Full Text] [Related]
22. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
Gattermann N
Hematol Oncol Clin North Am; 2020 Apr; 34(2):465-473. PubMed ID: 32089223
[TBL] [Abstract][Full Text] [Related]
23. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellström-Lindberg E; Cermák J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Mądry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luño E; Bowen D; de Witte T
Br J Haematol; 2015 Aug; 170(3):372-83. PubMed ID: 25907546
[TBL] [Abstract][Full Text] [Related]
24. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
25. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.
Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jädersten M; Jansson M; Elena C; Gallì A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungström V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Hellström Lindberg E
Blood; 2015 Jul; 126(2):233-41. PubMed ID: 25957392
[TBL] [Abstract][Full Text] [Related]
26. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
Wong CAC; Wong SAY; Leitch HA
Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
[TBL] [Abstract][Full Text] [Related]
27. Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes.
Hasserjian RP; Buckstein R; Patnaik MM
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():328-350. PubMed ID: 34010050
[TBL] [Abstract][Full Text] [Related]
28. Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.
Leitch HA; Buckstein R; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Shamy A; Elemary M; Wells RA
Leuk Res; 2018 Nov; 74():21-41. PubMed ID: 30286330
[TBL] [Abstract][Full Text] [Related]
29. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis.
Leitch HA; Chan C; Leger CS; Foltz LM; Ramadan KM; Vickars LM
Leuk Res; 2012 Nov; 36(11):1380-6. PubMed ID: 22921191
[TBL] [Abstract][Full Text] [Related]
30. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2017 Mar; 92(3):297-310. PubMed ID: 28188970
[TBL] [Abstract][Full Text] [Related]
31. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.
de Swart L; Reiniers C; Bagguley T; van Marrewijk C; Bowen D; Hellström-Lindberg E; Tatic A; Symeonidis A; Huls G; Cermak J; van de Loosdrecht AA; Garelius H; Culligan D; Macheta M; Spanoudakis M; Panagiotidis P; Krejci M; Blijlevens N; Langemeijer S; Droste J; Swinkels DW; Smith A; de Witte T;
Haematologica; 2018 Jan; 103(1):69-79. PubMed ID: 29122992
[TBL] [Abstract][Full Text] [Related]
32. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract][Full Text] [Related]
33. Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry.
Lyons RM; Marek BJ; Paley C; Esposito J; Garbo L; DiBella N; Garcia-Manero G
Leuk Res; 2014 Feb; 38(2):149-54. PubMed ID: 24314590
[TBL] [Abstract][Full Text] [Related]
34. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
[TBL] [Abstract][Full Text] [Related]
35. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
36. Iron overload in patients with myelodysplastic syndromes: An updated overview.
Moukalled NM; El Rassi FA; Temraz SN; Taher AT
Cancer; 2018 Oct; 124(20):3979-3989. PubMed ID: 29905937
[TBL] [Abstract][Full Text] [Related]
37. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.
Buckstein R; Wells RA; Zhu N; Leitch HA; Nevill TJ; Yee KW; Leber B; Sabloff M; St Hilaire E; Kumar R; Geddes M; Shamy A; Storring J; Kew A; Elemary M; Levitt M; Lenis M; Mamedov A; Zhang L; Rockwood K; Alibhai SM
Br J Haematol; 2016 Jul; 174(1):88-101. PubMed ID: 26991631
[TBL] [Abstract][Full Text] [Related]
38. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.
Strupp C; Nachtkamp K; Hildebrandt B; Giagounidis A; Haas R; Gattermann N; Bennett JM; Aul C; Germing U
Leuk Res; 2017 Jun; 57():78-84. PubMed ID: 28324772
[TBL] [Abstract][Full Text] [Related]
39. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.
Shingai N; Harada Y; Iizuka H; Ogata Y; Doki N; Ohashi K; Hagihara M; Komatsu N; Harada H
Int J Hematol; 2018 Dec; 108(6):598-606. PubMed ID: 30353274
[TBL] [Abstract][Full Text] [Related]
40. Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes.
Zeidan AM; Giri S; DeVeaux M; Ballas SK; Duong VH
Ann Hematol; 2019 Feb; 98(2):339-350. PubMed ID: 30413901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
